Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDHT PET/CT imaging to assess enzalutamide activity in metastatic breast cancer
MOH_2023-04-10_012517Phase 3Not yet recruiting
- Sponsor
- ד"ר מרינה עורבי
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enzalutamide in breast cancer, sponsored by ד"ר מרינה עורבי. Primary endpoints: Concordance of metastatic lesion location between FDG PET/CT and FDHT PET/CT and Predictive value of baseline and post-treatment FDG and FDHT uptake. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-04-10_012517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-10_012517.